Krebs Biochemicals & Industries Ltd
Krebs Biochemicals & Industries Ltd Live Price Chart
Krebs Biochemicals & Industries Ltd Technicals
| 20 Day | ₹ 61.506 |
| 50 Day | ₹ 65.254 |
| 100 Day | ₹ 69.047 |
| 200 Day | ₹ 73.497 |
| 20 Day | ₹ 62.342 |
| 50 Day | ₹ 65.883 |
| 100 Day | ₹ 69.502 |
| 200 Day | ₹ 74.433 |
Krebs Biochemicals & Industries Ltd Performance
| Previous Close | ₹ 58.77 |
| High | ₹ 59.6 |
| Volume | 16187 |
| 52W Range | ₹ 53.05 - ₹ 113.5 |
| Open | ₹ 58.78 |
| Low | ₹ 54 |
| Market Cap | ₹ 138 Cr |
Krebs Biochemicals & Industries Ltd Fundamentals
| ROCE | -19.172 |
| P/E Ratio | -4.470 |
| P/B Ratio | 0.000 |
| Industry P/E | 0.000 |
| Debt to Equity | 39.699 |
| ROE | 17.421 |
| EPS | -12.740 |
| Dividend Yield | 0.000 |
| Book Value | -73.146 |
| Face Value | 10.000 |
Krebs Biochemicals & Industries Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 44.0208 | 50.8728 | 52.7546 | 60.8589 | 54.3217 |
| Total Expenses | 70.9448 | 70.6012 | 77.4465 | 105.3857 | 82.6803 |
| Profit After Tax | -26.9393 | -19.7284 | -24.6919 | -44.5268 | -28.3586 |
Krebs Biochemicals & Industries Ltd Shareholding Pattern
| Promoter Holdings | 72.745 % |
| FIIs | 0.487 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 19.797 % |
| Others - | 6.971 % |
About Krebs Biochemicals & Industries Ltd
History of Krebs Biochemicals & Industries Ltd
Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991. The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003. Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process. The Company commissioned 2.5 MW Co-generation Power Plant at Unit II in Vizag during 2003-04 and started operations on it from July, 2004 onwards. Production of two new products has commenced in the Nellore unit of the company during 2008. The sales from Unit II showed a healthy increase and small activity started in Unit I through Contract Manufacturing in 2010-11. The steep drop in income was attributed to discontinuing of Lovastat ...
